TCR2 Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
58
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$165M
- Investors
-
3
TCR2 Therapeutics General Information
Description
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.
Contact Information
Website
www.tcr2.comCorporate Office
- 100 Binney Street
- Suite 710
- Cambridge, MA 02142
- United States
Corporate Office
- 100 Binney Street
- Suite 710
- Cambridge, MA 02142
- United States
TCR2 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 06-Mar-2023 | $165M | Completed | Generating Revenue | ||
| 6. 2PO | 21-Jan-2021 | Completed | Generating Revenue | |||
| 5. 2PO | 29-Jul-2020 | Completed | Generating Revenue | |||
| 4. IPO | 14-Feb-2019 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 21-Mar-2018 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 07-Dec-2016 | $44.5M | $44.5M | Completed | Startup | |
| 1. Early Stage VC | 01-Jan-2015 | Completed | Startup |
TCR2 Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
TCR2 Therapeutics Comparisons
Industry
Financing
Details
TCR2 Therapeutics Competitors (64)
One of TCR2 Therapeutics’s 64 competitors is Northwest Biotherapeutics, a Corporation company based in Bethesda, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Northwest Biotherapeutics | Corporation | Bethesda, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Monte Rosa Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA |
TCR2 Therapeutics Patents
TCR2 Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023235479-A1 | Compositions and methods for treating cancer | Inactive | 02-Jun-2022 | ||
| WO-2023172967-A2 | Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins | Inactive | 09-Mar-2022 | ||
| WO-2023172967-A3 | Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins | Inactive | 09-Mar-2022 | ||
| WO-2023133424-A2 | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides | Inactive | 05-Jan-2022 | ||
| WO-2023133424-A3 | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides | Inactive | 05-Jan-2022 | A61K40/11 |
TCR2 Therapeutics Signals
TCR2 Therapeutics Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 6 Dimensions Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| ArrowMark Partners | Asset Manager | Minority | ||
| Cathay Capital | PE/Buyout | Minority | ||
| Curative Ventures | Venture Capital | Minority |
TCR2 Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
TCR2 Therapeutics FAQs
-
When was TCR2 Therapeutics founded?
TCR2 Therapeutics was founded in 2015.
-
Where is TCR2 Therapeutics headquartered?
TCR2 Therapeutics is headquartered in Cambridge, MA.
-
What is the size of TCR2 Therapeutics?
TCR2 Therapeutics has 58 total employees.
-
What industry is TCR2 Therapeutics in?
TCR2 Therapeutics’s primary industry is Drug Discovery.
-
Is TCR2 Therapeutics a private or public company?
TCR2 Therapeutics is a Private company.
-
What is the current valuation of TCR2 Therapeutics?
The current valuation of TCR2 Therapeutics is .
-
What is TCR2 Therapeutics’s current revenue?
The current revenue for TCR2 Therapeutics is .
-
How much funding has TCR2 Therapeutics raised over time?
TCR2 Therapeutics has raised $509M.
-
Who are TCR2 Therapeutics’s investors?
6 Dimensions Capital, Alexandria Venture Investments, ArrowMark Partners, Cathay Capital, and Curative Ventures are 5 of 13 investors who have invested in TCR2 Therapeutics.
-
Who are TCR2 Therapeutics’s competitors?
Northwest Biotherapeutics, Kite Pharma, Monte Rosa Therapeutics, Carisma Therapeutics, and Allogene Therapeutics are some of the 64 competitors of TCR2 Therapeutics.
-
When was TCR2 Therapeutics acquired?
TCR2 Therapeutics was acquired on 06-Mar-2023.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process